Departments & Programs
  • Adrenal Tumors
  • Bladder Cancer
  • Bone Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colon Cancer
  • Gallbladder Cancer
  • Gastrointestinal Cancer
  • Head and Neck Cancer
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Ovarian Cancer
  • Pancreatic Cancer
  • Parathyroid Cancer
  • Pediatric Brain Tumors
  • Pituitary Tumors
  • Prostate Cancer
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer
  • Urethral Cancer
  • Uterine Cancer
  • Vaginal Cancer

Quality of Cancer Care

We are an American College of Surgeon's Commission on Cancer (CoC) ) accredited program. As part of this accreditation, The University of Vermont Cancer Center submits data on compliance with key metrics related to the standard of care therapies for breast and colon cancers.

These data are compiled annually into Cancer Program Practice Profile Reports (CP3R) which offer patients and providers meaningful information that helps us improve quality of patient care. We are pleased to report that based on this data, The UVM Medical Center outperforms or is on par with other Commission on Cancer approved programs across the country in these metrics.

The University of Vermont Medical Center, Burlington, VT (2015 diagnosis year)


Select Measures - Breast Cancer

Measure Commission on Cancer Standard University of Vermont Medical Center 2015 All Commission on Cancer Approved Programs 2015
Image or palpation-guided needle biopsy (core or FNA) of the primary site is performed to establish diagnosis of breast cancer 80% 98.60% 91.00%
Tamoxifen or third generation aromotase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage IB-III hormone receptor positive breast cancer 90% 98.50% 91.40%
Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with >= 4 positive regional lymph nodes 90% 100.00% 84.10%
Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer 90% 100.00% 86.70%
Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer 90% 96.40% 91.10%

Select Measures - Colon Cancer

Measure Commission on Cancer Standard University of Vermont Medical Center 2015 All Commission on Cancer Approved Programs 2015
At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer 85% 100.00% 92.00%

Select Measures - Rectal Cancer

Measure Commission on Cancer Standard University of Vermont Medical Center 2015 All Commission on Cancer Approved Programs 2015
Preoperative chemo and radiation administered for clinical AJCC T3N0, T4N0 or Stage III; or postoperative chemo and radiation administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0 or Stage III; or treatment is recommended; for patients under the age of 80 receiving resection for rectal cancer 85% 87.50% 87.00%

Select Measures - Lung Cancer

Measure Commission on Cancer Standard University of Vermont Medical Center 2015 All Commission on Cancer Approved Programs 2015
Systemic chemotherapy administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is recommended for surgically resected cases with pathologic lymph node positive (pN1) and (pN2) non-small cell lung cancer 85% 100.00% 89.00%
Surgery is not the first course of treatment for cN2 M0 lung cases 85% 100.00% 92.00%

Select Measures - Gastric Cancer

Measure Commission on Cancer Standard University of Vermont Medical Center 2015 All Commission on Cancer Approved Programs 2015
At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer 80% 50.00% 61.20%